Us Congress 2025-2026 Regular Session

Us Congress House Bill HB922

Introduced

2/4/25

Refer

2/4/25

Caption

Period PROUD (Providing Resources for Our Underserved and Disadvantaged) Act of 2025

Impact

The Act is positioned as a crucial public health measure that acknowledges the unmet need for menstrual products and the stigma often associated with menstruation. By providing funding for states and eligible entities, the bill aims to address these health risks and improve overall well-being for low-income menstruating individuals. Additionally, it outlines allowable uses of the funds, emphasizing the importance of community outreach and partnerships with local nonprofit organizations to ensure effective distribution and accessibility of these products.

Summary

House Bill 922, known as the Period PROUD (Providing Resources for Our Underserved and Disadvantaged) Act of 2025, is aimed at increasing the availability of menstrual products for individuals with limited access who are of low-income status. The bill proposes targeted funding through the Social Services Block Grant program, and it seeks to ensure that individuals in need can receive these essential products without financial burden. It specifies an increase in funding to $1.9 billion for fiscal years 2025 through 2028, allocating $200 million annually specifically for menstrual products distribution efforts.

Contention

While the objective to support underserved communities is widely seen as beneficial, the bill may encounter discussions regarding its implementation and the adequacy of the proposed funding. Critics may question whether the allocated budgets and the frameworks set for distribution can effectively meet the diverse needs of various communities. Moreover, there might be debates surrounding the equity of access to menstrual products across different demographics, as well as concerns about how success metrics for this initiative will be evaluated effectively.

Congress_id

119-HR-922

Introduced_date

2025-02-04

Notable Aspects

In addition to providing funds for menstrual products, HB922 requires evaluations to assess the program's effectiveness by the end of 2031, ensuring that results are reported to Congress and made publicly available. This commitment to transparency and accountability highlights the importance of addressing menstrual equity not just as a sanitary issue but as a vital public health concern that intersects with economic equity and social justice.

Latest HB922 Activity

Companion Bills

No companion bills found.

Similar Bills

US HB2436

To amend the Internal Revenue Code of 1986 to treat distributions from health savings accounts for funeral expenses of the account beneficiary as qualified distributions.

US HB1219

Oral Health Products Inclusion Act

US HB685

Support And Value Expectant Moms and Babies Act of 2025 or the SAVE Moms and Babies Act of 2025This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved.Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner.The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner from also acting as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient.The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)